BIODOL THERAPEUTICS
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
BIODOL THERAPEUTICS
Social Links:
Industry:
Therapeutics
Founded:
2015-01-01
Address:
Clapiers, Languedoc-Roussillon, France
Country:
France
Website Url:
http://www.biodol.eu
Total Employee:
1+
Status:
Active
Total Funding:
4.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Font Awesome Apache Euro OVH OVH DNS OVH Mail
Similar Organizations
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
VetSource
VetSource is a pharmaceuticals company providing pet care medication and vaccination services.
Current Advisors List
Current Employees Featured
Founder
Investors List
V-Bio Ventures
V-Bio Ventures investment in Series A - Biodol Therapeutics
Official Site Inspections
http://www.biodol.eu
- Host name: cluster011.ovh.net
- IP address: 213.186.33.40
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
